Cancer Enzyme PHGDH Drives Immune Evasion Through Novel Non-Metabolic Pathway

This research reveals how cancer cells exploit a metabolic enzyme to evade immune surveillance, potentially improving cancer treatment strategies that could extend healthspan by preventing cancer progression.

Researchers studied PHGDH (phosphoglycerate dehydrogenase), an enzyme normally involved in serine amino acid synthesis that's frequently overexpressed in cancers. They investigated whether PHGDH contributes to cancer beyond its metabolic role.

Using cell culture experiments and mouse tumor models, scientists discovered that PHGDH increases PD-L1 expression independently of its enzymatic activity. PD-L1 is a protein that helps cancer cells hide from immune system detection. PHGDH accomplishes this by binding to RAF1 kinase and disrupting its normal regulation, activating downstream MEK/ERK signaling pathways that boost PD-L1 production.

Analysis of clinical tumor samples confirmed that higher PHGDH levels correlate with increased PD-L1 expression in human cancers. In preclinical studies, tumors with elevated PHGDH showed enhanced sensitivity to PD-1/PD-L1 immunotherapy blockade. Most significantly, combining PHGDH inhibitors with standard immunotherapy produced superior anti-tumor effects compared to either treatment alone.

These findings suggest a novel therapeutic approach for cancers with PHGDH overexpression, potentially improving treatment outcomes and survival rates. By targeting both metabolic vulnerabilities and immune evasion mechanisms simultaneously, this combination strategy could enhance the effectiveness of current cancer immunotherapies, contributing to better long-term health outcomes and extended lifespan for cancer patients.